2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 40

Increased Mortality in Indigenous North Americans Persons with Rheumatoid Arthritis Is Partially Explained By Psychiatric and Physical Comorbidity: a Population Based Study

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 223

Increased Platelet Reactivity in Gout: A Potential Mechanism for Adverse Cardiovascular Events

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 496

Increased Serum Lipids Under Tocilizumab Is Not Influenced By Methotrexate

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 189

Indocyanine Green (ICG) -Enhanced Fluorescence Optical Imaging (FOI) in Patients with Active Rheumatoid Arthritis; A Comparative Study with Ultrasound and Association with Biomarkers

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 556

Induction-Maintenance in Early RA: A Meta-Analysis of Trials Using MTX Plus Adalimumab As Induction Therapy

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 241

Inflammatory Syndrome in Polyarticular Gout – Description of a Previously Neglected Entity

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 836

Influence of B Cell Depletion By Monoclonal Anti CD20 Antibodies in Systemic Sclerosis: Results of a Randomized Placebo Controlled Trial

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 504

Influence of CDAI Measurement on the Decision of Community Rheumatologists to Initiate or Change Biologic Treatment

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 90

Influence of Susceptible HLA-DRB1 Alleles on Clinical Subphenotypes of Systemic Lupus Erythematosus in Koreans

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 7

Influence of TNF on Anti-Inflammatory Tyrosine-Hydroxylase-Positive Synovial Cells in Rheumatoid Arthritis and Osteoarthritis

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 201

Innate Lymphoid Cells Are Present at Normal Human Enthesis Providing a Potential Mechanism for Spondyloarthropathy Pathogenesis

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 423

Institutional and Regional Variation in Childhood SLE 30-Day Hospital Readmission Rates: A Comparative Effectiveness Research Using the Pediatric Health Information System Database

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 88

Integrating Evidence for Genetic Association and Natural Selection Helps Detect New Systemic Lupus Erythematosus Risk Loci in African-Americans

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 407

Inter-Observer Variability of the Histological Classification of Lupus Glomerulonephritis in Children

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 805

Interferon Activity in Early and Established SLE: Interferon Score Is Lower in Early Disease and Not Seen without Antibodies to Extractable Nuclear Antigens

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].